ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the ALX Oncology Third Quarter 2025 Financial Results Conference Call-In Webcast. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I would now like to turn the conference over to your host, Jason Letman. Please go ahead, sir. Thanks everyone, and welcome to our Q3 2025 results. I appreciate everybody spending some time with us this morning, and I'm looking forward to this update. On slide two here, before we start our presentation of housekeeping, here are our forward-looking statements for your review. So on the next slide, slide three here, here is the agenda and our plan for today. We're going to be providing an update on our key accomplishments in the third quarter of 2025. Most notably, we are very excited to share with you the data set that will be presented at CITSE this weekend from a pre-planned analysis of our Aspen 06 trial that showed CD47 expression as a key predictive biomarker for increasing durable clinical response with avorpacept and HER2-positive gastric cancer patients. So our goals for today are most importantly to share these detailed results with you as we believe this data set now clearly validates the role of CD47 in HER2-positive cancers. We will then give you a sense of how this data now impacts our development strategy for Avorpicep going forward. We will also be providing an update on our novel ALEKS 2004 EGFR-targeted ADC, which is now in the clinic. Today, we are also excited to be joined by Dr. Peter Schmid from Barts Cancer Institute in the UK, who is a key opinion leader in breast cancer...